To the full analysis
Bausch Health Companies stock: growth
BHCBausch Health Companies reported $10.27B in revenue for fiscal 2025, up 6.7% on the prior year, up 5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
12.6%
per year from 2006 to 2025, per share 7.8%
Earnings (Annual rate)
−1.5%
per year from 2006 to 2025, per share −6.5%
Free cash flow (Annual rate)
4%
per year from 2006 to 2025, per share −0.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 5.0% | −0.2% | 12.6% |
| Revenue per share | 4.1% | −1.0% | 7.8% |
| Earnings | no data | no data | −1.5% |
| Earnings per share | no data | no data | −6.5% |
| Free cash flow | 4.6% | −6.2% | 4.0% |
| Free cash flow per share | 3.7% | −6.9% | −0.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.07B | $210M | $477.13M |
| 2007 | $842.82M | $195.54M | $305.77M |
| 2008 | $757.18M | $199.9M | $182.33M |
| 2009 | $820.43M | $176.46M | −$208.36M |
| 2010 | $1.15B | −$208.19M | $246.37M |
| 2011 | $2.46B | $159.56M | $290.52M |
| 2012 | $3.48B | −$116.03M | $475.45M |
| 2013 | $5.77B | −$866.14M | $857M |
| 2014 | $8.2B | $881M | $1.82B |
| 2015 | $10.44B | −$268.66M | $1.9B |
| 2016 | $9.67B | −$2.41B | $1.8B |
| 2017 | $8.72B | $2.4B | $1.95B |
| 2018 | $8.38B | −$4.15B | $1.27B |
| 2019 | $8.6B | −$1.78B | $1.22B |
| 2020 | $8.03B | −$559M | $802M |
| 2021 | $8.43B | −$948M | $1.14B |
| 2022 | $8.12B | −$225M | −$996M |
| 2023 | $8.76B | −$592M | $760M |
| 2024 | $9.63B | −$46M | $1.26B |
| 2025 | $10.27B | $157M | $1B |
Revenue by region
Where Bausch Health Companies Inc. generates its revenue.
- United States and Puerto Rico60%
- China5%
- Canada4%
- Poland4%
- Mexico3%
- France2%
- Other22%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States and Puerto Rico | $6.25B | $5.23B | $5.01B | $5.16B | $4.79B | $4.89B | $4.84B | $5.19B | $5.77B | $6.14B | 59.8% |
| China | $300M | $331M | $361M | $368M | $341M | $490M | $413M | $441M | $496M | $493M | 4.8% |
| Canada | $320M | $326M | $319M | $339M | $331M | $343M | $351M | $366M | $402M | $417M | 4.1% |
| Poland | $140M | $201M | $218M | $231M | $238M | $280M | $278M | $319M | $350M | $382M | 3.7% |
| Mexico | $189M | $201M | $211M | $228M | $225M | $256M | $276M | $322M | $315M | $278M | 2.7% |
| France | $186M | $188M | $205M | $201M | $179M | $208M | $203M | $214M | $230M | $249M | 2.4% |
| Other | $2.29B | $2.25B | $2.06B | $2.07B | $1.92B | $1.97B | $1.77B | $1.9B | $2.07B | $2.31B | 22.5% |
| Total revenue | $9.67B | $8.72B | $8.38B | $8.6B | $8.03B | $8.43B | $8.12B | $8.76B | $9.63B | $10.27B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.